Elicio Therapeutics (ELTX) vs ImageneBio (IMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ImageneBio (IMA) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 48.5% versus a loss of 82.8%. Over five years, IMA leads with a -97.1% price change compared with -97.9% for ELTX. ImageneBio is the larger company by market cap ($48.5 million vs $47.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELTX | IMA |
|---|---|---|
| Share price | $1.81 | $4.26 |
| Market cap | $47.57M | $48.45M |
| 1-day change | -2.16% | -7.59% |
| YTD return | -77.26% | -38.26% |
| 1-year return | -82.79% | -48.49% |
| 5-year return | -97.92% | -97.07% |
| EPS (TTM) | $-2.16 | $-4.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.00 | $9.10 |
| 52-week low | $1.71 | $3.94 |
| Distance from 52-week high | -88.69% | -53.19% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +655.25% | +322.54% |
| Average volume | 340.72K | 13.04K |
| Shares outstanding | 26.28M | 11.37M |
| Employees | 33 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMA has outperformed ELTX by 34.3 percentage points over the past year.
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Healthcare · Biotechnology · 33 employees
About ImageneBio
IMA stock →ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
Healthcare · Biotechnology · 18 employees
ELTX vs IMA FAQ
Which is bigger, Elicio Therapeutics or ImageneBio?
ImageneBio (IMA) is larger, with a market capitalization of $48.45M compared with $47.57M for Elicio Therapeutics (ELTX).
Which stock has performed better over the past year, ELTX or IMA?
IMA returned -48.49% over the past 12 months, compared with -82.79% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are Elicio Therapeutics and ImageneBio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.